Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:51 2026-02-13 am EST			5-day change	1st Jan Change
360.00 ^CHF	+0.08%		+1.01%	+9.69%

Feb. 13	Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates	MT
Feb. 10	ROCHE HOLDINGS AG : Barclays keeps its Buy rating	ZD

ROCHE HOLDINGS AG : Goldman Sachs from Sell to Neutral

Published on 01/16/2026 at 03:17 am EST

MarketScreener with dpa-AFX Analyser

ROCHE HOLDING AG

+0.08%

The board of Goldman Sachs is no longer a Sell on the case. The broker is now neutral. The target price has been raised from CHF 260 to CHF 365.

Latest news about Roche Holding AG

Feb. 13	Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates	MT
Feb. 10	ROCHE HOLDINGS AG : Barclays keeps its Buy rating	ZD
Feb. 10	Swiss stocks - Factors to watch on February 10	RE
Feb. 09	Roche Kept at Buy as BofA Notes 'Solid' Efficacy Data for Multiple Sclerosis Drug	MT
Feb. 09	Avacta appoints new chief scientific officer, plans clinical trials	AN
Feb. 09	ROCHE HOLDINGS AG : JP Morgan sticks Neutral	ZD
Feb. 09	There is still plenty of value in the old economy
Feb. 09	Avacta Therapeutics Announces Executive Changes	CI
Feb. 09	Roche's fenebrutinib reduces disability progression in PPMS	RE
Feb. 08	Roche's Investigational Drug Trial Shows Reduction in Progression of Multiple Sclerosis	MT
Feb. 06	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Feb. 06	Japan's Nikkei rallies on earnings in unsteady trade before Sunday election	RE
Feb. 05	Japanese drugmakers slump after Trump unveils discount drug website	RE
Feb. 04	ChemoMetec, Roche Diagnostics to Explore Bioprocess Monitoring Technology Collaboration	MT
Feb. 04	Stadler Rail AG Announces Board Resignations	CI

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

Mar. 03 - UBS European Healthcare Conference

More about the company